Earnings call transcript: Exsitec posts strong Q3 2026 growth as stock edges higher

Exsitec’s Q3 2026 revenue rose 23% year on year, primarily driven by the Amesto acquisition, while organic growth slowed to 3% from 8% in Q2. Adjusted EBITA increased 18% to SEK 30 million, but its margin declined to 12.9% from 13.5%; order intake rose 23%, and recurring net software revenue increased 24% to SEK 270 million on a last-12-month basis. Exsitec estimated annual net cost savings of SEK 35 million from restructuring, with the full effect expected from Q1 2027, and its shares rose 0.91% in the reported session.

Analysis

The key debate is conversion, not bookings: management says order intake is largely organic, but projects and subsequent software/support revenue can take months to appear. That makes the 23% intake growth a leading indicator, not evidence that the 3% organic revenue pace has already turned. Sweden BI capacity constraints create a two-sided effect: unmet demand can defer revenue, while hiring and training may weigh on near-term utilization before capacity becomes productive. The Amesto restructuring adds a further tension—cost removal supports the 2027 margin bridge, but execution must not strip capacity from areas with demand.

The quality signal is the 14% organic growth in recurring software revenue. If sustained, a larger recurring mix should make growth less dependent on project timing and support earnings visibility; it does not by itself establish higher group margins. Treat the SEK 35m savings estimate as management’s run-rate target, not a near-term earnings uplift: full effect is indicated from Q1 2027, and customer retention and delivery capacity remain the checks.

Contrarian read: Q3’s slowdown may be partly seasonal and comp-driven, but investors should not dismiss it—the prior-year Q3 organic growth was 6%, and customer caution was still affecting consulting projects. Near term, limited surprise and no formal guidance argue against chasing the print. Over 1–3 months, monitor organic consulting growth, utilization/hiring, and conversion of order intake; over 6–18 months, the thesis depends on recurring growth and savings lifting EBITA per share without impairing delivery. The promotional valuation commentary supplies no usable independent valuation evidence.

Key Decisions for Investors

• No immediate event-driven trade in EXS: the modest reaction and lack of a direct forecast comparison leave the signal mixed. Consider a small, staged long only if the next report confirms improving organic growth and order-intake conversion, with margin stability as confirmation rather than relying on acquisition-led revenue.
• Track the conversion indicators: organic consulting revenue, utilization and headcount in constrained BI areas, recurring software growth, and customer retention in Norway after integration. Strong bookings without revenue conversion or adequate staffing would weaken the growth case.
• Treat the Q1 2027 savings realization as a catalyst, not a current earnings assumption. Reassess if management delays the savings timetable, reports renewed restructuring costs, or adjusted EBITA margin fails to improve as the cost actions take effect.
• Falsification: reduce or avoid the long thesis if organic growth remains near or below Q3’s 3% in the next reported quarters, recurring software organic growth materially slows, or delivery constraints persist while order intake fails to translate into revenue.